Abstract: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.

Abstract: This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor.

Abstract: Calcilytic compounds and methods of preparing them are disclosed. Methods of using the calcilytic compounds are also provided.

Abstract: This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein: R1 is aryl optionally substituted with CN, NO2, halogen or H; R2 is H, C1-C6 alkyl, C3-C7 cycloalkyl, or C3-C7 heterocycloalkyl; R3 is H, OH, O—C1-C6 alkyl, SH, S—C1-C6 alkyl, or F; R4 is H, C1-C6 alkyl R5 is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and R6 is aryl, heteroaryl.

Abstract: Novel calcilytic compounds and methods of using them are provided.

Abstract: Novel calcilytic compounds and methods of using them are provided.

Abstract: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.

Abstract: Novel calcilytic compounds and methods of using them are provided.

Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

Abstract: Novel Calcilytic compounds and methods of using them are provided.

Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.